Guanidino-substituted quinazolinone compounds as MC4-R agonists

Details for Australian Patent Application No. 2004249120 (hide)

Owner GlaxoSmithKline Novartis Vaccines and Diagnostics, Inc.

Inventors Bishop, Michael J.; Smith, Aaron; Swain, William R.; Musso, David L.; Speake, Jason D.; Thomson, Stephen A.; Conlee, Christopher R.; Barvian, Kevin K.; Thompson, Brian D.; Chauder, Brian A.; Chu, Daniel; Boyce, Rustum S.; Aurrecoechea, Natalia; De Armas Kuntz, Judith; Du, Kien S.

Agent FB Rice

Pub. Number AU-B-2004249120

PCT Pub. Number WO2004/112793

Priority 60/523,336 19.11.03 US; 60/473,317 23.05.03 US; 60/524,492 24.11.03 US

Filing date 21 May 2004

Wipo publication date 29 December 2004

Acceptance publication date 24 July 2008

International Classifications

A61P 3/04 (2006.01) Drugs for disorders of the metabolism

A61K 31/517 (2006.01) - ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine

A61K 31/519 (2006.01) - ortho- or peri-condensed with heterocyclic rings

A61K 31/525 (2006.01)

A61K 31/53 (2006.01) - having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine

A61P 3/10 (2006.01) Drugs for disorders of the metabolism

C07D 217/24 (2006.01) Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems

C07D 239/91 (2006.01) Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings

C07D 239/95 (2006.01) Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings

C07D 239/96 (2006.01) Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings

C07D 253/08 (2006.01) Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group

C07D 401/04 (2006.01) Heterocyclic compounds containing two or more hetero rings

C07D 401/06 (2006.01) Heterocyclic compounds containing two or more hetero rings

C07D 401/12 (2006.01) Heterocyclic compounds containing two or more hetero rings

C07D 401/14 (2006.01) Heterocyclic compounds containing two or more hetero rings

C07D 403/04 (2006.01) Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group

C07D 403/06 (2006.01) Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group

C07D 403/12 (2006.01) Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group

C07D 403/14 (2006.01) Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group

C07D 405/12 (2006.01) Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom

C07D 417/04 (2006.01) Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group

C07D 417/14 (2006.01) Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group

C07D 471/04 (2006.01) Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups

Event Publications

17 November 2005 PCT application entered the National Phase

  PCT publication WO2004/112793 Priority application(s): WO2004/112793

10 July 2008 Assignment before Grant

  GlaxoSmithKline; Chiron Corporation The application has been assigned to GlaxoSmithKline; Novartis Vaccines and Diagnostics, Inc.

24 July 2008 Application Accepted

  Published as AU-B-2004249120

20 November 2008 Standard Patent Sealed

12 November 2009 Alteration of Name

  The name of the applicant has been altered to GlaxoSmithKline; Novartis Vaccines and Diagnostics, Inc. 2005

15 December 2011 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This patent ceased under section 143(a), or Expired. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004249123-Methods and compositions for delivery of catecholic butanes for treatment of obesity

2004249116-Flexible liquid absorbing structure